Nuwellis Shareholders Approve Key Proposals to Support Growth and Financial Flexibility
Nuwellis Shareholders Approve Proposals for Financial Flexibility and Strategic Growth
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company specializing in fluid management solutions, announced that stockholders have approved all proposals presented at the recent Special Meeting of Stockholders, held virtually on August 4, 2025.
Key Approved Proposals
The approved measures are intended to enhance the company’s capital structure and provide greater flexibility for future growth. The proposals included:
Warrant Exercise Approval: Shareholders authorized the company to issue shares of common stock under the terms of its June 10, 2025 financing, following Nasdaq Listing Rule 5635(d). This decision enables Nuwellis to access the capital committed through the warrant offering.
Increase in Authorized Shares: The company’s Certificate of Incorporation will be amended to increase the number of authorized shares of common stock from 100 million to 200 million.
Reverse Stock Split Authorization: Shareholders approved an amendment allowing Nuwellis’ Board of Directors to enact a reverse stock split at a ratio ranging from 1-for-5 to 1-for-70. This measure is designed to help maintain the company’s compliance with Nasdaq listing requirements, if needed.
John Erb, Chief Executive Officer of Nuwellis, expressed gratitude for the shareholders’ support, highlighting the importance of these approvals in bolstering the company’s capital position and its ability to execute long-term strategies.
Official voting results will be available in the company’s upcoming filing with the U.S. Securities and Exchange Commission (SEC).
About Nuwellis
Nuwellis, Inc. is dedicated to advancing patient care for those suffering from fluid overload, primarily through its Aquadex SmartFlow® system—an innovative solution for ultrafiltration therapy. The company operates out of Minneapolis and has a subsidiary in Ireland.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system offers a clinically proven and flexible approach to removing excess fluid in patients with hypervolemia. It's indicated for both short-term and extended use in adults and pediatric patients over 20 kg who do not respond to conventional treatments, such as diuretics. All Aquadex treatments are administered by trained healthcare professionals in clinical settings under physician supervision.
Forward-Looking Statements
This article may include forward-looking statements related to future growth and market opportunities. These projections are based on current expectations and involve risks and uncertainties. Actual results could differ materially due to factors discussed in company filings with the SEC. Nuwellis does not undertake any obligation to update forward-looking statements unless required by law.
This content is for informational purposes only and does not constitute financial advice.
